Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
This research study focuses on adults with overweight or obesity to evaluate the safety and effects of a drug called UBT251 when taken together with other medicines like midazolam, caffeine, and warfarin. The goal is to understand how UBT251 influences the blood levels of these medicines by looking at how the body processes them. This study is a phase 1, open-label trial designed to assess treatment effects in participants with excess body weight. Participants will receive UBT251 through injections under the skin, with doses gradually increased during the study. At specific visits, they will also take an oral cocktail containing warfarin, caffeine, and midazolam to see how UBT251 affects the metabolism of these drugs. The study uses a single-sequence crossover design where each participant receives both treatments in a set order to compare results. Throughout the study, participants will undergo blood tests to measure the concentration of warfarin, caffeine, and midazolam over time, focusing on key measures like area under the curve and maximum concentration after a single dose. These evaluations will occur from the first dose up to about 156 days. Safety will be monitored through medical history, physical exams, vital signs, ECGs, and lab tests. The total participation time will depend on the study schedule, with a primary completion date set for April 2027.
Actively Recruiting
Researchers are studying the safety and effectiveness of UBT251 for people living with overweight or obesity. This clinical trial is a phase 2 study that compares different doses of UBT251 against a placebo, which contains no active medicine. The goal is to understand how UBT251 affects body weight and tolerability in adults with these conditions. Participants will be randomly assigned to receive various doses of UBT251 or a placebo, all given as injections under the skin of the abdomen. The study includes multiple parts where participants receive different dose levels, with some receiving a single dose and others multiple doses. Placebo injections are designed to look like UBT251 to maintain study blinding. During the trial, participants will be monitored for treatment-emergent adverse events and changes in body weight over several weeks. Blood samples will be taken to measure UBT251 levels in the body. The study involves regular visits for assessments including physical exams, vital signs, and lab tests, extending up to 33 weeks. Researchers will track safety, tolerability, and how the drug moves through the body to evaluate outcomes.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how the drug emraclidine moves through the body and its safety in healthy elderly adults aged 65 to 85 years. This Phase 1, randomized, placebo-controlled study aims to understand the drugs pharmacokinetics, tolerability, and any adverse events in this population. The trial is sponsored by AbbVie and focuses on basic science to gather important information about the drugs effects. Participants will receive oral doses of either emraclidine or a placebo for either 10 days or 17 days, depending on their assigned group. The study uses a sequential design with multiple groups receiving ascending oral doses to assess safety and how the drug is processed in the body. The intervention involves taking oral tablets while the research team monitors participants closely. During the study, participants will undergo various assessments including vital sign measurements, electrocardiograms ECGs, physical examinations, and laboratory tests. Researchers will track changes in safety scales such as the Columbia-Suicide Severity Rating Scale and movement disorder rating scales up to approximately 20 days. Blood samples will be collected to measure drug concentration and metabolism. The total observation period for adverse events may extend up to about 50 days, ensuring thorough safety monitoring.
Actively Recruiting
Researchers are studying how the length of fasting and temporarily stopping certain diabetes medicines called Glucagon-Like-Peptide 1 GLP-1 receptor agonists affect the amount of food remaining in the stomach. The study focuses on people who use liraglutide injected, oral semaglutide, or injected semaglutide to understand differences in stomach emptying. Participants involvement length depends on which GLP-1 medication they are currently using. Participants will be assigned to receive one of three treatments liraglutide injected under the skin once daily, oral semaglutide taken once daily, or semaglutide injected once weekly. The study evaluates stomach emptying after fasting following either a solid high-fat meal or a liquid meal, with measurements taken at multiple times after fasting begins. The study lasts up to approximately 178 days depending on the medication group. During the study, participants will undergo assessments including gastric ultrasound to check stomach contents at several time points after fasting. Researchers will measure if the stomach is empty or contains solids, as well as the volume of gastric contents. These evaluations occur at specific visits over the study period. The goal is to better understand the effects of fasting duration and pausing medication on stomach emptying in people using these diabetes treatments.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating ACCG-2671, a nonpeptide dual amylin and calcitonin receptor agonist, in a first-in-human study to assess its safety, tolerability, and how the body processes the drug. The study includes healthy adults and adults with obesity and investigates the impact of food on the drugs effects. This randomized, double-blind trial is sponsored by Aconcagua Bio, Inc. The study has three parts Part 1 tests single ascending oral doses of ACCG-2671 or placebo in healthy participants Part 2 assesses the effect of food on a single dose in healthy participants under fasted and fed states and Part 3 evaluates multiple ascending daily doses over 84 days in adults with obesity, including those on stable injectable GLP-1RA treatment. Safety committees review data before increasing doses. Participants will undergo screening and then receive assigned doses or placebo, with monitoring including clinical evaluations, laboratory tests, vital signs, and ECGs over specified periods ranging from 17 to 112 days depending on the study part. Researchers track adverse events and changes in various blood and heart function measures. The study runs from December 2025 to April 2027, with detailed follow-up during and after dosing periods.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating SAB01, an investigational bispecific monoclonal antibody targeting mast cells, in a first-in-human Phase 1 clinical trial involving healthy adult participants. The study aims to assess the safety, pharmacokinetics, and pharmacodynamics of single ascending doses of SAB01 administered subcutaneously and intravenously. This randomized, double-blind, placebo-controlled study includes up to 88 participants across planned and optional cohorts monitored by a Safety Review Committee. Participants receive a single dose of SAB01 or placebo via subcutaneous injection or intravenous infusion. The study has 7 planned cohorts for subcutaneous and intravenous administration and up to 4 optional cohorts based on emerging safety and pharmacological data. Dose levels for intravenous administration will not exceed those evaluated by subcutaneous injection. Participants are randomized in a 62 ratio to receive SAB01 or placebo within each cohort. During the study, participants undergo safety and tolerability assessments from Day 1 through Day 113, alongside evaluations of SAB01s plasma pharmacokinetic profile and pharmacodynamic effects. Researchers monitor bioavailability, clearance rates, volume of distribution, half-life, and immunogenicity. Participants are required to comply with all study procedures and are monitored with laboratory tests, physical examinations, and electrocardiograms to ensure health status throughout the study period.
Actively Recruiting
Healthy Volunteer
Researchers are studying the safety and how the body processes the drug SBS-147 in healthy adults aged 18 to 55 years. This Phase 1 trial is part of the HEAL Initiative and aims to identify any side effects when taking SBS-147 compared to a placebo. The study includes participants who do not have major health issues and are willing to follow study procedures. Participants are divided into two groups one group receives a single dose of SBS-147 or placebo, and the other group receives SBS-147 or placebo once or twice daily for 7 days. Those in the single-dose group stay in the clinic for 5 days, while those in the multiple-dose group stay for 10 days. Both groups complete an end-of-study visit, either on Day 8 or Day 14 depending on the dosing schedule. During the study, participants will have tests, blood draws, and questionnaires to monitor their health and how their body handles the drug. Researchers will watch for treatment-related side effects using specific criteria over 8 or 14 days. The study also measures how much SBS-147 and related substances are in the blood over time. Participants must be available for the full duration of the study and comply with all study procedures.
Actively Recruiting
Healthy Volunteer
Researchers are studying the safety, tolerability, and how the body processes pharmacokinetics a long-acting injectable drug called S-892216-LAI in healthy adults. This Phase 1 trial involves participants aged 18 to 55 years to better understand the effects of single and multiple doses of this investigational drug compared to a placebo. Participants will receive either a single dose of S-892216-LAI or placebo on Day 1 in the first treatment period. In the second treatment period, participants will receive multiple doses on Day 1 and Day 85. The study uses a randomized, parallel design and includes a placebo control with quadruple masking to keep the treatment assignment confidential. During the study, participants will be monitored closely for any treatment-emergent adverse events from Day 1 through up to Day 448, depending on the treatment period. Researchers will measure the drug and its metabolites in the blood at various timepoints to assess concentration levels and how quickly the drug reaches its maximum concentration. Participants will undergo regular evaluations for safety and drug levels over the course of the study, which may last up to approximately 15 months.